Immunotherapy

Panel 19 - (INTERACTIVE) Integrating Immunotherapy in the Definitive Setting in Radiation Oncology

10/24/2018
1:30 PM - 3:00 PM
Location: Room 304

Session Type: Panel
1.50 AMA PRA Category 1 Credits™
1.50 CAMPEP Credits
1.50 MDCB Credits

There have been a number of recent successes in the use of combination immunotherapy in the treatment of metastatic or advanced solid malignancies. Even more so, there are a number of clinical trials targeting the combination of immunotherapy with local therapy in metastatic cancers in order to elicit a synergistic effect. This combination takes into account evidence that radiation therapy to the tumor may convert it into an in situ vaccine as well as radiation's potential in creating a pro-inflammatory tumor micro environment. An area of recent interest in this strategy is the combination of novel immunotherapies with radiation therapy in the definitive and curative setting. The recent PACIFIC study, where an anti-PDL1 therapy was used in the consolidative setting after chemoradiotherapy for stage III Non-small cell lung cancer (NSCLC), showed a large benefit in progression-free survival and underscores this synergy. This session will review how best to implement such combination therapy in the curative setting as well as explore future novel trial designs to build upon the success in other treatment paradigms where radiation therapy is centered as the curative modality such as in early stage, HPV positive oropharyngeal cancer, and locally advanced unresectable bladder cancer.

Learning Objectives:

Presentations:

Percy Lee, MD

University of California, Los Angeles

Disclosure:
Employment
UCLA Medical Center: Associate Professor: Employee

Compensation
Varian Inc.: Consultant, Honoraria; Viewray: Honoraria

Leadership
Committee Co-Chair: Commitee Co-Chair

Biography:
Dr. Percy Lee is an Associate Professor and Vice Chair of Education for the Department of Radiation Oncology at the David Geffen School of Medicine at UCLA and the UCLA Jonsson Comprehensive Cancer Center. He serves as the Residency Training Program Director as well as the Director for the Medical Student Clerkship. Dr. Lee attended the Johns Hopkins University and graduated with the highest honors majoring in Biomedical Engineering with a concentration in Chemical Engineering. He attended Harvard Medical School and the Harvard-MIT Health Science and Technology program (HST) where he received his M.D., and graduated Magna cum laude. At Harvard, he was also a Howard Hughes Medical Institute fellow. He interned at the Massachusetts General Hospital and received specialty training in Radiation Oncology from Stanford University School of Medicine. Dr. Lee is the Clinical Director of the Stereotactic Body Radiation Therapy (SBRT) program and the Chief of Service for the Thoracic and GI Radiation Oncology programs in the department.

Presentation(s):

Send Email for Percy Lee


Assets

Panel 19 - (INTERACTIVE) Integrating Immunotherapy in the Definitive Setting in Radiation Oncology



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Panel 19 - (INTERACTIVE) Integrating Immunotherapy in the Definitive Setting in Radiation Oncology